Managing Patients With HER2+ Breast Cancer and Brain Metastasis: Slides

Download these expert-selected slides on optimal treatment of patients with HER2-positive breast cancer with brain metastases.
Sara Tolaney, MD, MPH
Format: Microsoft PowerPoint (.ppt)
File Size: 535 KB
Released: February 2, 2021

Acknowledgements

Provided by the National Comprehensive Cancer Network in partnership with Clinical Care Options, LLC
NCCN Logo

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Genentech, a member of the Roche Group
Puma Biotechnology, Inc.

Related Content

Commentary from Nelson F. Sanchez, MD, on caring for transgender individuals, from the healthcare disparities they face to how healthcare professionals can improve their care, from Clinical Care Options (CCO)

Nelson F. Sanchez, MD Released: June 28, 2022

Results from LUMINA trial showing very low local recurrence rate with omission of radiotherapy after breast-conserving surgery in patients with low-risk luminal A breast cancer, presented at ASCO 2022 and reported by Clinical Care Options (CCO)

Released: June 15, 2022

Exploratory analysis of EFS by residual cancer burden from KEYNOTE-522 evaluating neoadj pembrolizumab plus chemotherapy followed by adj pembrolizumab for early-stage TNBC, presented at ASCO 2022 and reported by Clinical Care Options (CCO)

Released: June 14, 2022

PALOMA-2 study: final OS analysis with palbociclib plus letrozole in ER-positive/HER2-negative advanced breast cancer, presented at ASCO 2022 and reported by Clinical Care Options (CCO)

Released: June 10, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings